# A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in Italy

> **NCT06058741** · — · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 150 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06058741
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-04
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06058741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06058741, "A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in Italy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06058741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*